Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 12/2017

01-12-2017 | Original Article

Trends in the Mortality of Hepatocellular Carcinoma in the United States

Authors: Eliza W. Beal, Dmitry Tumin, Ali Kabir, Dimitrios Moris, Xu-Feng Zhang, Jeffery Chakedis, Kenneth Washburn, Sylvester Black, Carl M. Schmidt, Timothy M. Pawlik

Published in: Journal of Gastrointestinal Surgery | Issue 12/2017

Login to get access

Abstract

Introduction

Primary liver cancer mortality rates have been increasing in the US, but reported decreases among 35–49 year olds may foreshadow future declines. We sought to use age-period-cohort (APC) modeling to evaluate the contribution of cohort effects to hepatocellular carcinoma (HCC) mortality trends in the US.

Methods

Data on HCC mortality were obtained from the Centers for Disease Control and Prevention National Center for Health Statistics WONDER Online Multiple Cause of Death database, 1999–2015. Crude mortality rates were plotted by gender and age at death. Gender-specific restricted cubic spline APC models were fit to determine influence of birth cohort on incidence of HCC mortality, in reference to the 1940 birth cohort.

Results

Highest mortality rates were found among men ages 70+, with steepest increase in mortality observed among men 55–69 years old. Similar trends were found among females. Accounting for the cohort effect in the APC model markedly improved model fit (likelihood ratio test p < 0.001). Relative to the 1940 birth cohort, risk of mortality due to HCC was significantly higher in later as well as earlier cohorts.

Conclusions

HCC-associated mortality continues to increase, secondary to an increase in the risk of HCC-associated mortality in more recent birth cohorts among both men and women.
Literature
1.
go back to reference Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108.CrossRefPubMed Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108.CrossRefPubMed
2.
go back to reference Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C, et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl. 2017; 23(6):836–844. doi:10.1002/lt.24758. Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C, et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl. 2017; 23(6):836–844. doi:10.​1002/​lt.​24758.
3.
go back to reference Murali AR, Patil S, Phillips KT, Voigt M. Locoregional therapy with curative intent versus primary liver transplant for hepatocellular carcinoma: systematic review and meta-analysis. Transplantation. 2017; 101(8):e249–e257. doi:10.1097/TP.0000000000001730. Murali AR, Patil S, Phillips KT, Voigt M. Locoregional therapy with curative intent versus primary liver transplant for hepatocellular carcinoma: systematic review and meta-analysis. Transplantation. 2017; 101(8):e249–e257. doi:10.​1097/​TP.​0000000000001730​.
4.
go back to reference Alver SK, Lorenz DJ, Marvin MR, Brock GN. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates. Liver Transpl. 2016; 22 (10):1343–55.CrossRefPubMed Alver SK, Lorenz DJ, Marvin MR, Brock GN. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates. Liver Transpl. 2016; 22 (10):1343–55.CrossRefPubMed
5.
go back to reference Alver SK, Lorenz DJ, Washburn K, Marvin MR, Brock GN. Comparison of two equivalent MELD scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry. Transpl Int. 2017. doi:10.1111/tri.12967. Alver SK, Lorenz DJ, Washburn K, Marvin MR, Brock GN. Comparison of two equivalent MELD scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry. Transpl Int. 2017. doi:10.​1111/​tri.​12967.
6.
go back to reference Ioannou GN. Transplant-related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma. Liver Transpl. 2017; 23(5):652–62.CrossRefPubMed Ioannou GN. Transplant-related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma. Liver Transpl. 2017; 23(5):652–62.CrossRefPubMed
7.
go back to reference Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastroenterol. 2017; 15(2):296–304. doi:10.1007/s11938-017-0133-3. Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastroenterol. 2017; 15(2):296–304. doi:10.​1007/​s11938-017-0133-3.
11.
go back to reference Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014; 109(4):542–53.CrossRefPubMedPubMedCentral Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014; 109(4):542–53.CrossRefPubMedPubMedCentral
12.
go back to reference Park J, Jee YH. Age-Period-Cohort Analysis of Liver Cancer Mortality in Korea. Asian Pac J Cancer Prev. 2015; 16 (18):8589–94.CrossRefPubMed Park J, Jee YH. Age-Period-Cohort Analysis of Liver Cancer Mortality in Korea. Asian Pac J Cancer Prev. 2015; 16 (18):8589–94.CrossRefPubMed
13.
go back to reference Tzeng IS, Lee WC. Forecasting hepatocellular carcinoma mortality in Taiwan using an age-period-cohort model. Asia Pac J Public Health. 2015; 27(2):NP65–73.CrossRefPubMed Tzeng IS, Lee WC. Forecasting hepatocellular carcinoma mortality in Taiwan using an age-period-cohort model. Asia Pac J Public Health. 2015; 27(2):NP65–73.CrossRefPubMed
14.
go back to reference Akita T, Ohisa M, Kimura Y, Fujimoto M, Miyakawa Y, Tanaka J. Validation and limitation of age-period-cohort model in simulating mortality due to hepatocellular carcinoma from 1940 to 2010 in Japan. Hepatol Res. 2014; 44(7):713–9.CrossRefPubMed Akita T, Ohisa M, Kimura Y, Fujimoto M, Miyakawa Y, Tanaka J. Validation and limitation of age-period-cohort model in simulating mortality due to hepatocellular carcinoma from 1940 to 2010 in Japan. Hepatol Res. 2014; 44(7):713–9.CrossRefPubMed
15.
go back to reference Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017.
16.
go back to reference Statistics. C-NCfDCaPNCfH. Multiple Cause of Death 1999–2015 on CDC WONDER Online Database, Released December 2016. Statistics. C-NCfDCaPNCfH. Multiple Cause of Death 1999–2015 on CDC WONDER Online Database, Released December 2016.
17.
18.
go back to reference Rutherford MJ, Lambert PC, Thompson JR. Age–period–cohort modeling. The Stata Journal. 2010; 10(4):606–27. Rutherford MJ, Lambert PC, Thompson JR. Age–period–cohort modeling. The Stata Journal. 2010; 10(4):606–27.
19.
go back to reference Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989; 8(5):551–61.CrossRefPubMed Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989; 8(5):551–61.CrossRefPubMed
20.
go back to reference White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017; 152(4):812–20.e5.CrossRefPubMed White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017; 152(4):812–20.e5.CrossRefPubMed
21.
go back to reference Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9(1):64–70.CrossRefPubMed Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9(1):64–70.CrossRefPubMed
22.
go back to reference Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127 (5 Suppl 1):S35–50.CrossRefPubMed Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127 (5 Suppl 1):S35–50.CrossRefPubMed
23.
go back to reference Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016; 36 Suppl 1:47–57.CrossRefPubMed Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016; 36 Suppl 1:47–57.CrossRefPubMed
24.
25.
go back to reference Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148(3):547–55.CrossRefPubMed Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148(3):547–55.CrossRefPubMed
28.
go back to reference Unzueta A, Cabrera R. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. Clin Liver Dis. 2017;21(2):231–51.CrossRefPubMed Unzueta A, Cabrera R. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. Clin Liver Dis. 2017;21(2):231–51.CrossRefPubMed
29.
go back to reference Gavriilidis P, Askari A, Azoulay D. Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 2017; 19(1):3–9.CrossRefPubMed Gavriilidis P, Askari A, Azoulay D. Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 2017; 19(1):3–9.CrossRefPubMed
Metadata
Title
Trends in the Mortality of Hepatocellular Carcinoma in the United States
Authors
Eliza W. Beal
Dmitry Tumin
Ali Kabir
Dimitrios Moris
Xu-Feng Zhang
Jeffery Chakedis
Kenneth Washburn
Sylvester Black
Carl M. Schmidt
Timothy M. Pawlik
Publication date
01-12-2017
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 12/2017
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-017-3526-7

Other articles of this Issue 12/2017

Journal of Gastrointestinal Surgery 12/2017 Go to the issue